629 related articles for article (PubMed ID: 28392690)
1. Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo.
Jian YS; Chen CW; Lin CA; Yu HP; Lin HY; Liao MY; Wu SH; Lin YF; Lai PS
Int J Nanomedicine; 2017; 12():2315-2333. PubMed ID: 28392690
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo.
Zhong Y; Goltsche K; Cheng L; Xie F; Meng F; Deng C; Zhong Z; Haag R
Biomaterials; 2016 Apr; 84():250-261. PubMed ID: 26851390
[TBL] [Abstract][Full Text] [Related]
3. Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery.
Yang Y; Zhao Y; Lan J; Kang Y; Zhang T; Ding Y; Zhang X; Lu L
Int J Nanomedicine; 2018; 13():4361-4378. PubMed ID: 30100720
[TBL] [Abstract][Full Text] [Related]
4. Smart nanoparticles with a detachable outer shell for maximized synergistic antitumor efficacy of therapeutics with varying physicochemical properties.
Yin T; Liu J; Zhao Z; Dong L; Cai H; Yin L; Zhou J; Huo M
J Control Release; 2016 Dec; 243():54-68. PubMed ID: 27702595
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronan magnetic nanoparticle for mitoxantrone delivery toward CD44-positive cancer cells.
Sargazi A; Shiri F; Keikha S; Majd MH
Colloids Surf B Biointerfaces; 2018 Nov; 171():150-158. PubMed ID: 30025377
[TBL] [Abstract][Full Text] [Related]
6. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models.
Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z
J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726
[TBL] [Abstract][Full Text] [Related]
7. CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release.
Lin CW; Lu KY; Wang SY; Sung HW; Mi FL
Acta Biomater; 2016 Apr; 35():280-92. PubMed ID: 26853764
[TBL] [Abstract][Full Text] [Related]
8. CD44 targeting biocompatible and biodegradable hyaluronic acid cross-linked zein nanogels for curcumin delivery to cancer cells: In vitro and in vivo evaluation.
Seok HY; Sanoj Rejinold N; Lekshmi KM; Cherukula K; Park IK; Kim YC
J Control Release; 2018 Jun; 280():20-30. PubMed ID: 29723613
[TBL] [Abstract][Full Text] [Related]
9. Intracellular delivery and antitumor effects of a redox-responsive polymeric paclitaxel conjugate based on hyaluronic acid.
Yin S; Huai J; Chen X; Yang Y; Zhang X; Gan Y; Wang G; Gu X; Li J
Acta Biomater; 2015 Oct; 26():274-85. PubMed ID: 26300335
[TBL] [Abstract][Full Text] [Related]
10. Redox-Responsive and Dual-Targeting Hyaluronic Acid-Methotrexate Prodrug Self-Assembling Nanoparticles for Enhancing Intracellular Drug Self-Delivery.
Zhang Y; Li Y; Tian H; Zhu Q; Wang F; Fan Z; Zhou S; Wang X; Xie L; Hou Z
Mol Pharm; 2019 Jul; 16(7):3133-3144. PubMed ID: 31198046
[TBL] [Abstract][Full Text] [Related]
11. Hyaluronic acid-decorated liposomal nanoparticles for targeted delivery of 5-fluorouracil into HT-29 colorectal cancer cells.
Mansoori B; Mohammadi A; Abedi-Gaballu F; Abbaspour S; Ghasabi M; Yekta R; Shirjang S; Dehghan G; Hamblin MR; Baradaran B
J Cell Physiol; 2020 Oct; 235(10):6817-6830. PubMed ID: 31989649
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional tumor-targeting nanocarriers based on hyaluronic acid-mediated and pH-sensitive properties for efficient delivery of docetaxel.
Song S; Chen F; Qi H; Li F; Xin T; Xu J; Ye T; Sheng N; Yang X; Pan W
Pharm Res; 2014 Apr; 31(4):1032-45. PubMed ID: 24154802
[TBL] [Abstract][Full Text] [Related]
13. Dual targeting system by supramolecular complex of folate-conjugated methyl-β-cyclodextrin with adamantane-grafted hyaluronic acid for the treatment of colorectal cancer.
Elamin KM; Motoyama K; Higashi T; Yamashita Y; Tokuda A; Arima H
Int J Biol Macromol; 2018 Jul; 113():386-394. PubMed ID: 29486262
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronic Acid-Coated Camptothecin Nanocrystals for Targeted Drug Delivery to Enhance Anticancer Efficacy.
Wang J; Muhammad N; Li T; Wang H; Liu Y; Liu B; Zhan H
Mol Pharm; 2020 Jul; 17(7):2411-2425. PubMed ID: 32437163
[TBL] [Abstract][Full Text] [Related]
15. CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis.
Serafino A; Zonfrillo M; Andreola F; Psaila R; Mercuri L; Moroni N; Renier D; Campisi M; Secchieri C; Pierimarchi P
Curr Cancer Drug Targets; 2011 Jun; 11(5):572-85. PubMed ID: 21486216
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion.
Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y
Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386
[TBL] [Abstract][Full Text] [Related]
17. Targeted intracellular protein delivery based on hyaluronic acid-green tea catechin nanogels.
Liang K; Ng S; Lee F; Lim J; Chung JE; Lee SS; Kurisawa M
Acta Biomater; 2016 Mar; 33():142-52. PubMed ID: 26785145
[TBL] [Abstract][Full Text] [Related]
18. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
19. Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma.
Lee SJ; Ghosh SC; Han HD; Stone RL; Bottsford-Miller J; Shen DY; Auzenne EJ; Lopez-Araujo A; Lu C; Nishimura M; Pecot CV; Zand B; Thanapprapasr D; Jennings NB; Kang Y; Huang J; Hu W; Klostergaard J; Sood AK
Clin Cancer Res; 2012 Aug; 18(15):4114-21. PubMed ID: 22693353
[TBL] [Abstract][Full Text] [Related]
20. Phytosterol-loaded CD44 receptor-targeted PEGylated nano-hybrid phyto-liposomes for synergistic chemotherapy.
Gautam M; Thapa RK; Gupta B; Soe ZC; Ou W; Poudel K; Jin SG; Choi HG; Yong CS; Kim JO
Expert Opin Drug Deliv; 2020 Mar; 17(3):423-434. PubMed ID: 32028805
[No Abstract] [Full Text] [Related]
[Next] [New Search]
